​

Atrium Therapeutics (RNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNA Stock Rating

Atrium Therapeutics stock's rating consensus is Hold, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (43.75%), 9 Hold (56.25%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 16 0 9 7 Strong Sell Sell Hold Buy Strong Buy

RNA Price Target Upside V Benchmarks

TypeNameUpside
StockAtrium Therapeutics-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$13.49$13.49$13.49
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-1---1
Mar, 26-1---1
Feb, 26-212--14
Jan, 26-212--14
Dec, 25-311--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 18, 2025Evercore ISI$72.00$72.11-0.15%433.73%
Oct 28, 2025Keay NakaeChardan Capital$72.00$70.002.86%433.73%
Oct 28, 2025Luca IssiRBC Capital$72.00$70.002.86%433.73%
Oct 28, 2025Keay NakaeLoop Capital Markets$72.00$70.002.86%433.73%
Oct 27, 2025Market PerformLeerink Partners$72.00$69.952.93%433.73%
Oct 27, 2025Boobalan PachaiyappanRoth Capital$72.00$49.1546.49%433.73%
Oct 27, 2025Market PerformBernstein$72.00$49.1546.49%433.73%
Oct 27, 2025H.C. Wainwright$72.00$49.1546.49%433.73%
Sep 17, 2025Roth Capital$62.00$40.0654.77%359.60%
Sep 10, 2025Eric SchmidtCantor Fitzgerald$96.00$46.40106.90%611.64%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 12, 2025Cowen & Co.HoldHoldhold
Oct 29, 2025Cowen & Co.BuyHolddowngrade
Oct 28, 2025RBC CapitalSector Performdowngrade
Oct 27, 2025CitigroupBuyNeutraldowngrade
Oct 27, 2025Roth CapitalNeutraldowngrade
Oct 27, 2025CitigroupBuyBuyhold
Oct 27, 2025NeedhamBuyHolddowngrade
Oct 27, 2025Raymond JamesStrong BuyMarket Performdowngrade
Oct 27, 2025BernsteinOutperformMarket Performdowngrade
Oct 27, 2025H.C. WainwrightBuyNeutraldowngrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.85$-3.34$-2.91$-2.89$-4.97---
Avg Forecast$-2.73$-3.36$-2.65$-2.87$-3.30$-3.57$-1.85$1.53
High Forecast$-2.11$-2.07$-1.86$-2.70$-2.45$-2.17$-0.03$2.24
Low Forecast$-3.34$-4.83$-2.98$-2.99$-4.49$-4.63$-3.20$0.81
Surprise %4.40%-0.60%9.81%0.70%50.61%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.33M$9.22M$9.56M$10.90M$18.75M---
Avg Forecast$9.51M$8.32M$19.58M$9.74M$7.11M$21.89M$307.80M$861.96M
High Forecast$11.16M$11.13M$46.62M$12.09M$9.67M$22.88M$418.75M$1.17B
Low Forecast$7.87M$5.87M$5.92M$7.46M$4.54M$20.90M$196.62M$550.63M
Surprise %-1.98%10.84%-51.17%11.87%163.95%---

Net Income Forecast

$-700M $-520M $-340M $-160M $20M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-118.01M$-174.00M$-212.22M$-322.30M$-684.63M---
Avg Forecast$-199.05M$-245.03M$-212.22M$-207.69M$-253.46M$-248.49M$-118.09M$111.56M
High Forecast$-154.36M$-151.35M$-136.14M$-197.17M$-179.08M$-158.64M$-2.51M$163.85M
Low Forecast$-243.66M$-352.61M$-217.24M$-218.20M$-327.84M$-338.34M$-233.67M$59.18M
Surprise %-40.71%-28.99%-55.19%170.11%---

RNA Forecast FAQ

Is Atrium Therapeutics stock a buy?

Atrium Therapeutics stock has a consensus rating of Hold, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Atrium Therapeutics is a neutral investment for most analysts.

What is Atrium Therapeutics's price target?

Atrium Therapeutics's price target, set by 16 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $13.49.

How does Atrium Therapeutics stock forecast compare to its benchmarks?

Atrium Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Atrium Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 14.29% Buy, 85.71% Hold, 0% Sell, 0% Strong Sell.

What is Atrium Therapeutics’s EPS forecast?

Atrium Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.57, marking a -28.17% decrease from the reported $-4.97 in 2025. Estimates for the following years are $-1.85 in 2027, and $1.53 in 2028.

What is Atrium Therapeutics’s revenue forecast?

Atrium Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $21.89M, reflecting a 16.71% increase from the reported $18.76M in 2025. The forecast for 2027 is $307.8M, and $861.96M for 2028.

What is Atrium Therapeutics’s net income forecast?

Atrium Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-248M, representing a -63.70% decrease from the reported $-685M in 2025. Projections indicate $-118M in 2027, and $111.56M in 2028.